Launch of Sensipod - First Point of Care Test Thu, 26th Sep 2013 07:00 RNS Number : 9171O Avacta Group PLC 26 September 2013
26 September 2013
Avacta Group plc
Launch of the Sensipod in-clinic blood testing system for vets
First point of care test to provide a canine environmental allergy pre-screen
Avacta Group plc (AIM: AVCT), a provider of diagnostic tools, consumables and reagents used in human and animal healthcare, announces that it has launched its in-clinic blood analysis system, Sensipod, to veterinary practices in the UK along with the first point of care test to screen dogs for environmental allergies.
Sensipod is an in-clinic diagnostic system designed to detect a wide range of markers of disease by rapidly carrying out an enzyme linked immunosorbent assay (ELISA) test - the gold standard for diagnostic tests - on a small sample of blood. The system is being launched in the UK with its first test, a canine environmental allergy pre-screen that assists the veterinarian in identifying allergies in dogs. Avacta is currently developing a large panel of additional tests for Sensipod covering common diseases in dogs, cats and horses, as well as other novel tests, which will provide a unique bench-top diagnostic capability for the veterinarian.
At the heart of the Sensipod system is an innovative single use cartridge, pre-loaded with test specific reagents, and the Sensipod bench-top instrument. The single use cartridge is capable of carrying out all of the steps of an ELISA test without any additional user interaction and provides a sensitive measure of disease biomarkers. When the full panel of tests is complete the Sensipod will equip vets with a state-of-the-art device that will provide a quick and easy diagnosis of some of the most common companion animal diseases.
The Sensipod in-clinic system complements Avacta's established reference laboratory diagnostic services which it provides to veterinarians in the UK, and its diagnostic test kits which it provides to third party reference laboratories globally. The programme of expansion of the Sensipod test menu will also generate new laboratory tests and diagnostic kits to expand the existing offering in these routes to market.
Alastair Smith, Chief Executive of Avacta Group said:
"I am absolutely delighted that Sensipod has now launched and is in the hands of veterinarians. A huge amount of hard work and innovation has delivered a product that we believe has massive potential in the veterinary market. Growth of the test menu is key to realising that potential. We are making good progress in that area and anticipate reporting the launch of a number of new tests during this financial year. Our initial focus for commercialisation of Sensipod is the UK and we have plans to address other geographical markets as the test menu grows.
"New reference laboratory tests and diagnostic kits
Lemonaider I can understand your irritation at the notion that you should feel warm inside even if AVCT shares fall. I totally agree with you.....most of us buy shares to generate a tangible, worthwhile profit, in my case to supplement my retirement income. In post-Blairite Britain we are unfortunately still surrounded by all these Chablis socialists who want to eat their fair trade chocolate, drive Citroens, work for Quangos and bask in political correctness! Some of them can clearly well afford to feign the concept of making money! There's plenty of them at Brighton this week.
Rest assured, beyond all the hype, Avacta continues to come across as an excellent company engaged in solid, globally valuable and highly marketable technology. They appear to be very well managed by a highly experienced and diverse board of directors which they continue to expand. Above all, they appear to remain on course as a good medium to long term investment. And there may be the rub....in today's stressed-out, impatient world, the barrow boy traders of the 80's who now run (infest) many of the UK's investment banks are often only really interested in the short term? I am confident that the majority of small to medium investors in Avacta together with its major share holders, will continue to retain their position for the next two to five years, at least. Good Luck for the future and...stick with them. I'm sure it will be worth it!!
With all due respect to Sukithedog, if I want to feel good about myself, I'll donate to charity directly. When I buy shares my aim is to make money, and all hype aside, this company has gloriously failed to do so yet. Sorry.
Current 0.90 (-3.23%) Prices delayed 15 minutes Get Alert A Cosy Feeling Going On – ref Avacta and Advanced Oncotherapy By Malcolm Stacey — Wednesday 18 September 2013
Share this article with your comrades in revolutionary capitalism
Disclosure: I own shares in one or more of the stocks mentioned. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from ShareProphets). I have no business relationship with any company whose stock is mentioned in this article.
Hello Gang: There is a warm feeling to be had from investing in certain companies. Because you know that even if you lose a bit of money, you will still be doing some good.
The kind of stock I have in mind is the medical share. Not the big drugs companies – though they fund a lot of useful research. But the smaller firm which is doing modest research of its own and is coming up with treatments that are worthwhile.
There are many quite small firms out there which are doing exciting stuff in the world of medical research. They supply hospitals all over the world with equipment and drugs that bring real relief and even some cures.
Now, if you put your money into oil companies, for example, you have it at the back of your mind that you are not really helping the planet. Yes, some big oil companies are spending a lot of our gelt on finding green alternatives to oil, but they are also producing the black stuff, which has nasty effects on the air.
Sadly, this will not put me off buying into oil companies. I know that it is a volatile sector and my money has a goodly chance of rocketing. (It has an equally good chance of disappearing fast, but it's a risk we take for a bit of excitement these days.)
But I am investing in quite a few small medical outfits. Two of them – and this is not a recommendation to buy, because I just don't know if I'm right - are Advanced Oncotherapy (AVO) who do cancer treatments and the other is Avacta Group (AVCT).
Advanced soared just before I wrote this on a juicy deal in America. The Avacta share did really well a few months ago and it then went into a nasty decline. However, they make really useful medical instruments. We all know that there is more and more demand for medical products as most of us are living longer.
And even if these two shares lose dosh for me, at least I know that, somewhere, my money maybe helped somebody out of a bit of misery and pain. And that aim is worth more than share profits, as we all know... in the Punter's Return.
To get Twitter updates from ShareProphets as they happen
The Analysis & Comment section of ShareProphets is independent financial commentary. These blogs do not represent the opinions of ShareProphets Ltd. and does not therefore accept responsibility for or make any warranties in connection with or recommend that you or any third par
Shares in Avacta (AVCT) are up 11% today 0.91p but the hot money is heading in and reckons that the shares could be heading for 2p before too long.
The reason for today’s rise is that the provider of diagnostic tools, consumables and reagents aimed at reducing the cost of human and animal healthcare appointed Dr Matt Johnson to lead the Group's Affimer technology development and production teams. Dr Johnson joins Avacta from Abcam plc where he was Head of R&D.
Datafeed and UK data supplied by NETbuilder and Interactive Data.
While London South East do their best to maintain the high quality of the information displayed on this site,
we cannot be held responsible for any loss due to incorrect information found here. All information is provided free of charge, 'as-is', and you use it at your own risk.
The contents of all 'Chat' messages should not be construed as advice and represent the opinions of the authors, not those of London South East Limited, or its affiliates.
London South East does not authorise or approve this content, and reserves the right to remove items at its discretion.